Sisram Medical FY2025 Injectables Revenue More Than Doubled to USD 28 million, Revenue Rose 4.7% to USD 365 million

Reuters

Yesterday

Sisram Medical FY2025 Injectables Revenue More Than Doubled to USD 28 million, Revenue Rose 4.7% to USD 365 million

Sisram published an annual results announcement reporting revenue of USD 365.3 million, up 4.7%.
Gross profit margin was 58.9%, down 3.2 percentage points, which management attributed to geographic and product mix changes and newly established import tariffs.
Profit for the year was USD 25.01 million, down 13.1%, while adjusted net profit was USD 31.0 million, up 7.9%.
Revenue from injectables was USD 28.0 million, up more than doubled, driven mainly by the establishment of a direct sales office in Thailand that accelerated Profhilo’s ramp-up.
The board declared a final dividend of HKD 0.095 per share.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sisram Medical Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260323-12063760), on March 23, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2621936704"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2621936704\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2621936704?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 22:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621936704","market":"us","top_or_hot":-1,"title":"Sisram Medical FY2025 Injectables Revenue More Than Doubled to USD 28 million, Revenue Rose 4.7% to USD 365 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sisram Medical FY2025 Injectables Revenue More Than Doubled to USD 28 million, Revenue Rose 4.7% to USD 365 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Sisram published an annual results announcement reporting revenue of USD 365.3 million, up 4.7%.\n        </li>\n<li>\n          Gross profit margin was 58.9%, down 3.2 percentage points, which management attributed to geographic and product mix changes and newly established import tariffs.\n        </li>\n<li>\n          Profit for the year was USD 25.01 million, down 13.1%, while adjusted net profit was USD 31.0 million, up 7.9%.\n        </li>\n<li>\n          Revenue from injectables was USD 28.0 million, up more than doubled, driven mainly by the establishment of a direct sales office in Thailand that accelerated Profhilo’s ramp-up.\n        </li>\n<li>\n          The board declared a final dividend of HKD 0.095 per share.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sisram Medical Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260323-12063760), on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sisram Medical FY2025 Injectables Revenue More Than Doubled to USD 28 million, Revenue Rose 4.7% to USD 365 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSisram Medical FY2025 Injectables Revenue More Than Doubled to USD 28 million, Revenue Rose 4.7% to USD 365 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-23 22:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sisram Medical FY2025 Injectables Revenue More Than Doubled to USD 28 million, Revenue Rose 4.7% to USD 365 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Sisram published an annual results announcement reporting revenue of USD 365.3 million, up 4.7%.\n        </li>\n<li>\n          Gross profit margin was 58.9%, down 3.2 percentage points, which management attributed to geographic and product mix changes and newly established import tariffs.\n        </li>\n<li>\n          Profit for the year was USD 25.01 million, down 13.1%, while adjusted net profit was USD 31.0 million, up 7.9%.\n        </li>\n<li>\n          Revenue from injectables was USD 28.0 million, up more than doubled, driven mainly by the establishment of a direct sales office in Thailand that accelerated Profhilo’s ramp-up.\n        </li>\n<li>\n          The board declared a final dividend of HKD 0.095 per share.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sisram Medical Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260323-12063760), on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1100","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL4zg1Wf:1","article_id":"2621936704","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621936704","pubTimestamp":1774275732,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sisram published an annual results announcement reporting revenue of USD 365.3 million, up 4.7%.Gross profit margin was 58.9%, down 3.2 percentage points, which management attributed to geographic and product mix changes and newly established import tariffs.Profit for the year was USD 25.01 million, down 13.1%, while adjusted net profit was USD 31.0 million, up 7.9%.Revenue from injectables was USD 28.0 million, up more than doubled, driven mainly by the establishment of a direct sales office in Thailand that accelerated Profhilo’s ramp-up.The board declared a final dividend of HKD 0.095 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sisram Medical Ltd. published the original content used to generate this news brief via IIS,","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1100":"医疗保健设备","01696":"复锐医疗科技","00656":"复星国际","BK1593":"医美概念股","BK1585":"昨日强势股","BK1230":"工业集团企业"},"translate_title":"Sisram Medical 2025财年注射剂收入增长一倍多，达到2800万美元，收入增长4.7%，达到3.65亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01696":0.9,"00656":0.9},"content_text":"Sisram Medical FY2025 Injectables Revenue More Than Doubled to USD 28 million, Revenue Rose 4.7% to USD 365 million\n    \n\n\n          Sisram published an annual results announcement reporting revenue of USD 365.3 million, up 4.7%.\n        \n\n          Gross profit margin was 58.9%, down 3.2 percentage points, which management attributed to geographic and product mix changes and newly established import tariffs.\n        \n\n          Profit for the year was USD 25.01 million, down 13.1%, while adjusted net profit was USD 31.0 million, up 7.9%.\n        \n\n          Revenue from injectables was USD 28.0 million, up more than doubled, driven mainly by the establishment of a direct sales office in Thailand that accelerated Profhilo’s ramp-up.\n        \n\n          The board declared a final dividend of HKD 0.095 per share.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sisram Medical Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260323-12063760), on March 23, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}